91 related articles for article (PubMed ID: 11781639)
1. Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and..
Gordon LI
Bone Marrow Transplant; 2001 Nov; 28(9):811-2. PubMed ID: 11781639
[No Abstract] [Full Text] [Related]
2. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
Tack DK; Letendre L; Kamath PS; Tefferi A
Bone Marrow Transplant; 2001 Nov; 28(9):895-7. PubMed ID: 11781652
[TBL] [Abstract][Full Text] [Related]
3. Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis.
O'Boyle KP; Murigeppa A; Jain D; Dauber L; Dutcher JP; Wiernik PH
Med Oncol; 2003; 20(4):379-84. PubMed ID: 14716035
[TBL] [Abstract][Full Text] [Related]
4. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of gemtuzumab-associated hepatic sinusoidal occlusion syndrome after hematopoietic stem cell transplant.
Aplenc R; Vachani A; Han P; Glatfelter W; Sievers EL
Acta Haematol; 2003; 110(4):207-10. PubMed ID: 14663169
[No Abstract] [Full Text] [Related]
8. Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).
Bastie JN; Suzan F; Garcia I; Isnard F; de Revel T; Terre C; Mayeur D; Abraham C; Lavielle R; Castaigne S
Br J Haematol; 2002 Mar; 116(4):924. PubMed ID: 11886404
[No Abstract] [Full Text] [Related]
9. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
Giles FJ; Cortes JE; Halliburton TA; Mallard SJ; Estey EH; Waddelow TA; Lim JT
Ann Pharmacother; 2003 Sep; 37(9):1182-5. PubMed ID: 12921496
[TBL] [Abstract][Full Text] [Related]
10. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide.
Saviola A; Luppi M; Potenza L; Morselli M; Ferrari A; Riva G; Torelli G
Br J Haematol; 2003 Nov; 123(4):752-3. PubMed ID: 14616990
[No Abstract] [Full Text] [Related]
11. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
[TBL] [Abstract][Full Text] [Related]
12. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Rajvanshi P; Shulman HM; Sievers EL; McDonald GB
Blood; 2002 Apr; 99(7):2310-4. PubMed ID: 11895761
[TBL] [Abstract][Full Text] [Related]
13. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.
Versluys B; Bhattacharaya R; Steward C; Cornish J; Oakhill A; Goulden N
Blood; 2004 Mar; 103(5):1968. PubMed ID: 14976063
[No Abstract] [Full Text] [Related]
15. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Giles F; Garcia-Manero G; O'Brien S; Estey E; Kantarjian H
Acta Haematol; 2002; 108(3):164-7. PubMed ID: 12373091
[No Abstract] [Full Text] [Related]
16. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
McKoy JM; Angelotta C; Bennett CL; Tallman MS; Wadleigh M; Evens AM; Kuzel TM; Trifilio SM; Raisch DW; Kell J; DeAngelo DJ; Giles FJ
Leuk Res; 2007 May; 31(5):599-604. PubMed ID: 16959316
[TBL] [Abstract][Full Text] [Related]
17. Possible association between Budd-Chiari Syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia.
Kurt M; Shorbagi A; Altundag K; Elkiran T; Güllü I; Kansu E
Am J Hematol; 2005 Nov; 80(3):213-5. PubMed ID: 16247755
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
[TBL] [Abstract][Full Text] [Related]
19. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
Shannon-Dorcy K
Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin.
Viele CS
Clin J Oncol Nurs; 2002; 6(5):298-9, 304. PubMed ID: 12240495
[No Abstract] [Full Text] [Related]
[Next] [New Search]